Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on LongTermValue Research’s Substack. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $185.28 as of March 16th. VEEV’s trailing and forward P/E were 34.06 and 20.92 respectively according to Yahoo Finance.
Veeva Systems, Inc. (VEEV) represents a rare opportunity to invest in a durable, high-margin vertical SaaS business at an attractive valuation. The company specializes in cloud applications tailored for life sciences, including pharma and biotech, embedding itself deeply into workflows that are expensive, highly regulated, and difficult to replace. While its CRM business has drawn market attention due to competitive pressure from Salesforce and a recent platform migration, CRM represents only ~20% of revenue, and churn among Top-20 pharma clients is gradual and manageable.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The broader Veeva suite, now spanning ~50 applications across commercialization and drug development, benefits from structural moats, high switching costs, and audit-compliant data lineage, making its platform essential and sticky. Transitioning CRM to its Vault platform enhances cross-selling opportunities and introduces AI-driven capabilities that automate labor-intensive workflows like pharmacovigilance and electronic trial master file management, delivering tangible cost savings and measurable productivity improvements.
These AI initiatives are embedded, auditable, and economically significant, positioning Veeva as a vertical market AI leader rather than a generic SaaS provider. Financially, Veeva boasts best-in-class metrics, including ~17% five-year revenue CAGR, ~40% FCF margins, strong FCF/net income conversion, minimal dilution, and a net cash balance of $6.4 billion, enabling strategic optionality. The market’s >25% equity drawdown misprices the company, overlooking its diversified revenue base, resilient cash flows, and AI tailwinds.
As CRM competitive fears abate, AI adoption accelerates, and the broader suite expands, VEEV is poised for re-rating, with a projected 83% upside to ~$400 by end-2027, implying a 27% IRR. Investors benefit from a combination of immediate cash flow, durable growth, and optionality around AI monetization and CRM stabilization, making Veeva a compelling long-term compounder at a discounted entry point.
Previously, we covered a bullish thesis on Veeva Systems Inc. (VEEV) by Francesco Ferrari in March 2025, which highlighted the company’s high-margin recurring revenue model, strong financial performance, and resilient position in life sciences cloud software. VEEV’s stock price has depreciated by approximately 22.68% since our coverage. LongTermValue Research shares a similar view but emphasizes AI-driven workflow automation, Vault CRM transition, and broader suite expansion, highlighting additional catalysts for re-rating and upside toward ~$400 by end-2027.
Veeva Systems Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 75 hedge fund portfolios held VEEV at the end of the fourth quarter which was 57 in the previous quarter. While we acknowledge the risk and potential of VEEV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VEEV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
